COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,544 Articles (22,881 medRxiv, 8,663 bioRxiv)

Most recent first Previous |  Page 877: Articles 8761-8770  | Next

Impact of spatiotemporal heterogeneity in COVID-19 disease surveillance on epidemiological parameters and case growth rates
Inward, R., Parag, K. V., Jackson, F., Kraemer, M., Lindstrom Battle, A., Dasgupta, A., Lee, G., Global.health consortium
10.1101/2022.03.31.22273230 — Posted: 2022-03-31
Global Reports of Myocarditis Following COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Ahmed, S. K., Mohamed, M. G., Essa, R. A., Ahmed Rashad, E. A., Ibrahim, P. K., Khdir, A. A., Wsu, Z. H.
10.1101/2022.03.27.22273007 — Posted: 2022-03-31
Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage
Kulasinghe, A., Liu, N., Tan, C. W., Monkman, J., Sinclair, J. E., Bhuva, D. D., Godbolt, D., Pan, L., Nam, A., Sadeghirad, H., Sato, K., Li Bassi, G., O'Byrne, K., Hartmann, C., Miggiolaro, A. F. R. d. S., Marques, G. L., Moura, L. Z., Richard, D., Adams, M. N., Noronha, L., Baena, C. P., Suen, J., Arora, R., Belz, G. T., Short, K., Davis, M. J., Guimaraes, F. S., Fraser, J. F.
10.1101/2022.03.24.22272732 — Posted: 2022-03-31
Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial
Pannus, P., Depickere, S., Kemlin, D., Houben, S., Neven, K. Y., Heyndrickx, L., Michiels, J., Willems, E., De Craeye, S., Francotte, A., Chaumont, F., Olislagers, V., Waegemans, A., Verbrugghe, M., Schmickler, M.-N., Van Gucht, S., Dierick, K., Marchant, A., Desombere, I., Arien, K. K., Goossens, M. M.
10.1101/2022.03.25.22272599 — Posted: 2022-03-31
A 21L/BA.2-21K/BA.1 MixOmicron SARS-CoV-2 hybrid undetected by qPCR that screen for variant in routine diagnosis
Colson, P., Delerce, J., Marion-Paris, E., Lagier, J.-C., Bedotto, M., LEVASSEUR, A., Fournier, P.-E., LA SCOLA, B., Raoult, D.
10.1101/2022.03.28.22273010 — Posted: 2022-03-31
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV: a nationwide prospective cohort study in the Netherlands
Hensley, K. S., Jongkees, M. J., Geers, D., GeurtsvanKessel, C. H., Mueller, Y. M., Dalm, V. A. S. H., Papageorgiou, G., Steggink, H., Gorska, A., Bogers, S., den Hollander, J. G., Bierman, W. F. W., Gelinck, L. B. S., Schippers, E. F., Ammerlaan, H. S. M., van der Valk, M., van Vonderen, M. G. A., Delsing, C. E., Gisolf, E. H., Bruns, A. H. W., Lauw, F. N., Berrevoets, M. A. H., Sigaloff, K. C. E., Soetekouw, R., Branger, J., de Mast, Q., Lammers, A. J. J., Lowe, S. H., de Vries, R. D., Katsikis, P. D., Rijnders, B. J. A., Brinkman, K., Roukens, A. H. E., Rokx, C.
10.1101/2022.03.31.22273221 — Posted: 2022-03-31
A Wide-bandwidth Nanocomposite-Sensor Integrated Smart Mask for Tracking Multi-phase Respiratory Activities for COVID-19 Endemic
Suo, J., Liu, Y., Wu, C., Chen, M., Huang, Q., Liu, Y., Yao, K., Chen, Y., Pan, Q., Chang, X., Chan, H.-y., Zhang, G., Yang, Z., Daoud, W., Li, X., Vellaisamy, R., Yu, X., Wang, J., Li, W. J.
10.1101/2022.03.28.22273021 — Posted: 2022-03-31
SARS-CoV-2 Omicron is specifically restricted in its replication in human lung tissue, compared to other variants of concern
Alfi, O., Hamdan, M., Wald, O., Yakirevitch, A., Wandel, O., Oiknine-Djian, E., Gvili, B., Knoller, H., Rozendorn, N., Golan Berman, H., Adar, S., Vorontsov, O., Mandelboim, M., Zakay-Rones, Z., Oberbaum, M., Panet, A., Wolf, D.
10.1101/2022.03.31.486531 — Posted: 2022-03-31
No magic bullet: limiting in-school transmission in the face of variable SARS-CoV-2 viral loads
Van Egeren, D., Stoddard, M., Malakar, A., Ghosh, D., Acharya, A., Mainuddin, S., Majumdar, B., Luo, D., Nolan, R., Joseph-McCarthy, D., White, L. F., Hochberg, N. S., Basu, S., Chakravarty, A.
10.1101/2022.03.25.22272956 — Posted: 2022-03-31
Prediction of infectivity of SARS-CoV2: Mathematical Model with Docking Simulation analysis between Spike Protein and ACE2
Takaoka, Y., Sugano, A., Morinaga, Y., Ohta, M., Miura, K., Kataguchi, H., Kumaoka, M., Kimura, S., Maniwa, Y.
10.1101/2022.03.30.486373 — Posted: 2022-03-31

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).